Literature DB >> 8776427

Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and/or metastatic squamous cell carcinoma of the head and neck.

M Degardin, P Cappelaere, I Krakowski, P Fargeot, D Cupissol, S Brienza.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8776427     DOI： 10.1016/0964-1955(95)00082-8

Source DB:  PubMed          Journal:  Eur J Cancer B Oral Oncol        ISSN： 0964-1955


× No keyword cloud information.
  5 in total

Review 1.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

Review 2.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Authors:  C R Culy; D Clemett; L R Wiseman
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

3.  Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.

Authors:  Daniel G Stover; A Craig Lockhart; Jordan D Berlin; Emily Chan; Alan B Sandler; Jeffery A Sosman; Victoria Middlebrook; Steven Nicol; Mace L Rothenberg
Journal:  Invest New Drugs       Date:  2008-05-08       Impact factor: 3.850

4.  Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer.

Authors:  Joseph I Clark; Joshua B Greene; Ann Lau Clark; Jay S Dalal; Craig C Hofmeister
Journal:  Med Oncol       Date:  2012-12-25       Impact factor: 3.738

5.  Assessment of antitumor activity and acute peripheral neuropathy of 1,2-diaminocyclohexane platinum (II)-incorporating micelles (NC-4016).

Authors:  Takayoshi Ueno; Kazuhira Endo; Kiyomi Hori; Noriyuki Ozaki; Akira Tsuji; Satoru Kondo; Naohiro Wakisaka; Shigeyuki Murono; Kazunori Kataoka; Yasuki Kato; Tomokazu Yoshizaki
Journal:  Int J Nanomedicine       Date:  2014-06-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.